
-
Cogent Biosciences Inc NasdaqGS:COGT Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Location: 275 Wyman Street, Waltham, MA, 02451, United States | Website: https://www.cogentbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
506.9M
Cash
245.7M
Avg Qtr Burn
-55.44M
Short % of Float
21.16%
Insider Ownership
0.16%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) + Sunitinib Details Cancer, Gastrointestinal stromal tumors | Phase 3 Data readout | |
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) Details Advanced systemic mastocytosis (AdvSM) | Phase 2 Data readout | |
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) Details Nonadvanced systemic mastocytosis | Phase 2 Data readout | |
CGT4859 (FGFR2 inhibitor) Details Advanced cholangiocarcinoma | Phase 1 Data readout | |
CGT4255 / CNS-penetrant ErbB2 program Details Solid tumor/s | IND Submission |